CIL002

CIL002 is a preclinical-stage therapeutic candidate being developed by Cilcare for the treatment of synaptopathy. Synaptopathy in the context of auditory health refers to the loss or dysfunction of synapses between the inner hair cells and the auditory nerve fibers, a condition often referred to as "hidden hearing loss" because it may not be detectable by standard audiograms. This condition can be triggered by noise exposure, aging, or certain ototoxic medications. While Cilcare has positioned CIL002 as a key asset in its neuro-otology pipeline, specific details regarding the drug's modality (e.g., small molecule, peptide) and its exact molecular target have not yet been publicly disclosed.